| Literature DB >> 29962691 |
Jalil Ur Rehman1,2,3, Muhammad Isa4,5, Nisar Ahmad1, Gulfam Nasar6, H M Noor Ul Huda Khan Asghar1, Zaheer Abbas Gilani1, James C L Chow4, Muhammad Afzal2, Geoffrey S Ibbott3.
Abstract
This analysis estimated secondary cancer risks after volumetric modulated arc therapy (VMAT) and compared those risks to the risks associated with other modalities of head-and-neck (H&N) radiotherapy. Images of H&N anthropomorphic phantom were acquired with a computed tomography scanner and exported via digital imaging and communications in medicine (DICOM) standards to a treatment planning system. Treatment plans were performed using a VMAT dual-arc technique, a nine-field intensity-modulated radiation therapy (IMRT) technique, and a four-field three-dimensional conformal therapy (3DCRT) technique. The prescription dose was 66.0 Gy for all three techniques, but to accommodate the range of dosimeter responses, we delivered a single dose of 6.60 Gy to the isocenter. The lifetime risk for secondary cancers was estimated according to National Council on Radiation Protection and Measurements (NCRP) Report 116. VMAT delivered the lowest maximum doses to esophagus (23 Gy), and normal brain (40 Gy). In comparison, maximum doses for 3DCRT were 74% and 40%, higher than those for VMAT for the esophagus, and normal brain, respectively. The normal tissue complication probability and equivalent uniform dose for the brain (2.1%, 0.9%, 0.8% and 3.8 Gy, 2.6 Gy, 2.3 Gy) and esophagus (4.2%, 0.7%, 0.4% and 3.7 Gy, 2.2 Gy, 1.8 Gy) were calculated for the 3DCRT, IMRT and VMAT respectively. Fractional esophagus OAR volumes receiving more than 20 Gy were 3.6% for VMAT, 23.6% for IMRT, and 100% for 3DCRT. The calculations for mean doses, NTCP, EUD and OAR volumes suggest that the risk of secondary cancer induction after VMAT is lower than after IMRT and 3DCRT.Entities:
Keywords: EBT2 FILM; imaging and radiation oncology core; intensity-modulated radiation therapy; thermoluminescent dosimeter; three-dimensional conformal radiation therapy; volumetric modulated arc therapy
Year: 2018 PMID: 29962691 PMCID: PMC6020619 DOI: 10.4103/jmp.JMP_106_17
Source DB: PubMed Journal: J Med Phys ISSN: 0971-6203
Figure 1(a) Imaging and Radiation Oncology Core-Houston (formerly Radiological Physics Center) head-and-neck anthropomorphic phantom. (b) Standard imaging and radiation Oncology core insert that contains the simulated planning target volume and organs at risks
Figure 2Head-and-neck axial, sagittal, and coronal (left to right) images of (a) volumetric modulated arc therapy, (b) intensity-modulated radiation therapy, and (c) three-dimensional conformal radiation therapy, with absolute isodose lines of 660, 600, 500, 450, 400, 300, 200, and 150 cGy. These isodose values correspond to the doses delivered to the phantom, and were intended to represent patient doses of 66 Gy, etc
Figure 3Cumulative dose-volume histograms of planning target volume (a) brain (b), and esophagus (c) for treatment plans using three-dimensional conformal radiation therapy, intensity-modulated radiation therapy and volumetric modulated arc therapy
Maximum and mean doses to organs at risk for three-dimensional conformal therapy, intensity-modulated radiation therapy, and volumetric modulated arc therapy for head-and-neck radiotherapy
Volumes of organs at risk receiving doses greater than the secondary cancer risk thresholds of 20 Gy and 38 Gy
Lifetime secondary cancer risk for organs at risk by head-and-neck radiotherapy technique
Normal tissue complication probability and equivalent uniform dose of organs at risk